{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:05:43Z","timestamp":1789776343677,"version":"4.0.1"},"reference-count":59,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000738","name":"US Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jacc.2026.05.005","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T14:14:54Z","timestamp":1781705694000},"page":"373-388","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hypertension at an Inflection Point"],"prefix":"10.1016","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8355-7100","authenticated-orcid":false,"given":"Rajiv","family":"Agarwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.jacc.2026.05.005_bib1","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.jacc.2025.05.007","volume":"86","author":"Jones","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.jacc.2026.05.005_bib2","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1056\/NEJMoa2412006","article-title":"Intensive blood-pressure control in patients with type 2 diabetes","volume":"392","author":"Bi","year":"2025","journal-title":"N Engl J Med"},{"issue":"10449","key":"10.1016\/j.jacc.2026.05.005_bib3","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(24)01028-6","article-title":"Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial","volume":"404","author":"Liu","year":"2024","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jacc.2026.05.005_bib4","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/MNH.0000000000001163","article-title":"New pharmacological therapies for hypertension","volume":"35","author":"Saxena","year":"2026","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"11","key":"10.1016\/j.jacc.2026.05.005_bib5","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1161\/HYPERTENSIONAHA.122.19430","article-title":"Novel pharmacological approaches in the treatment of hypertension: a focus on RNA-based therapeutics","volume":"80","author":"Addison","year":"2023","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.jacc.2026.05.005_bib6","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfad251","article-title":"New trials in resistant hypertension: mixed blessing stories","volume":"17","author":"Zoccali","year":"2024","journal-title":"Clin Kidney J"},{"issue":"3","key":"10.1016\/j.jacc.2026.05.005_bib7","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000213334","article-title":"Long-term effect of intensive vs standard blood pressure control on mild cognitive impairment and probable dementia in SPRINT","volume":"104","author":"Reboussin","year":"2025","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.jacc.2026.05.005_bib8","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S1474-4422(20)30319-7","article-title":"Effects of intensive versus standard blood pressure control on domain-specific cognitive function: a substudy of the SPRINT randomised controlled trial","volume":"19","author":"Rapp","year":"2020","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.jacc.2026.05.005_bib9","doi-asserted-by":"crossref","DOI":"10.1161\/HYP.0000000000000258","article-title":"Single-pill combination therapy for the management of hypertension: a scientific statement from the American Heart Association","volume":"83","author":"King","year":"2026","journal-title":"Hypertension"},{"issue":"10367","key":"10.1016\/j.jacc.2026.05.005_bib10","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/S0140-6736(22)02034-7","article-title":"Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial","volume":"400","author":"Schlaich","year":"2022","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.jacc.2026.05.005_bib11","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1161\/HYP.0000000000000240","article-title":"Renal denervation for the treatment of hypertension: a scientific statement from the American Heart Association","volume":"81","author":"Cluett","year":"2024","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.jacc.2026.05.005_bib12","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/joim.70061","article-title":"Aldosterone synthase inhibitors across the translational spectrum: Mechanistic foundations and emerging clinical applications","volume":"299","author":"Merlo","year":"2026","journal-title":"J Intern Med"},{"issue":"12","key":"10.1016\/j.jacc.2026.05.005_bib13","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1080\/14712598.2024.2425343","article-title":"Will zilebesiran, an RNA interference therapy, be effective, safe, and improve the treatment of hypertension?","volume":"24","author":"Doggrell","year":"2024","journal-title":"Expert Opin Biol Ther"},{"issue":"22","key":"10.1016\/j.jacc.2026.05.005_bib14","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Wright","year":"2015","journal-title":"N Engl J Med"},{"issue":"10507","key":"10.1016\/j.jacc.2026.05.005_bib15","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S0140-6736(25)01391-1","article-title":"Benefit-harm trade-offs of intensive blood pressure control versus standard blood pressure control on cardiovascular and renal outcomes: an individual participant data analysis of randomised controlled trials","volume":"406","author":"Guo","year":"2025","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.jacc.2026.05.005_bib16","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","article-title":"Effects of intensive blood-pressure control in type 2 diabetes mellitus","volume":"362","author":"Cushman","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.005_bib17","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.5646\/ch.2025.31.e20","article-title":"Lowering of systolic blood pressure with ESPRIT along the BPROAD: the lower the better?","volume":"31","author":"Kreutz","year":"2025","journal-title":"Clin Hypertens"},{"issue":"5","key":"10.1016\/j.jacc.2026.05.005_bib18","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.14443","article-title":"Identifying patients for intensive blood pressure treatment based on cognitive benefit: a secondary analysis of the SPRINT randomized clinical trial","volume":"6","author":"Ghazi","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"12","key":"10.1016\/j.jacc.2026.05.005_bib19","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1161\/CIRCRESAHA.123.322001","article-title":"Pregnancy as an early cardiovascular moment: peripartum cardiovascular health","volume":"132","author":"Khan","year":"2023","journal-title":"Circ Res"},{"issue":"4","key":"10.1016\/j.jacc.2026.05.005_bib20","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jamainternmed.2025.7802","article-title":"Hypertensive disorders of pregnancy subtypes and long-term cardiovascular risk","volume":"186","author":"Kwak","year":"2026","journal-title":"JAMA Intern Med"},{"issue":"7","key":"10.1016\/j.jacc.2026.05.005_bib21","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1161\/CIRCULATIONAHA.125.078057","article-title":"Hypertensive disorders of pregnancy and premature cardiovascular disease in a diverse cohort of young US women","volume":"153","author":"Boyer","year":"2026","journal-title":"Circulation"},{"issue":"19","key":"10.1016\/j.jacc.2026.05.005_bib22","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa2201295","article-title":"Treatment for mild chronic hypertension during pregnancy","volume":"386","author":"Tita","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jacc.2026.05.005_bib23","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1097\/AOG.0000000000005410","article-title":"Perinatal outcomes associated with management of stage 1 hypertension","volume":"142","author":"Bailey","year":"2023","journal-title":"Obstet Gynecol"},{"issue":"20","key":"10.1016\/j.jacc.2026.05.005_bib24","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1001\/jama.2023.21523","article-title":"Long-term blood pressure control after hypertensive pregnancy following physician-optimized self-management: the POP-HT randomized clinical trial","volume":"330","author":"Kitt","year":"2023","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.jacc.2026.05.005_bib25","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1161\/CIRCULATIONAHA.123.067597","article-title":"Cardiac remodeling after hypertensive pregnancy following physician-optimized blood pressure self-management: the POP-HT randomized clinical trial imaging substudy","volume":"149","author":"Kitt","year":"2024","journal-title":"Circulation"},{"issue":"10361","key":"10.1016\/j.jacc.2026.05.005_bib26","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(22)01786-X","article-title":"Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial","volume":"400","author":"Mackenzie","year":"2022","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.jacc.2026.05.005_bib27","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1001\/jama.2025.4390","article-title":"Antihypertensive medication timing and cardiovascular events and death: the BedMed randomized clinical trial","volume":"333","author":"Garrison","year":"2025","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.jacc.2026.05.005_bib28","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.13812","article-title":"Bedtime vs morning antihypertensive medications in frail older adults: the BedMed-Frail randomized clinical trial","volume":"8","author":"Garrison","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"12","key":"10.1016\/j.jacc.2026.05.005_bib29","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1161\/HYPERTENSIONAHA.123.21892","article-title":"Influence of baseline diastolic blood pressure on the effects of intensive blood pressure lowering: results from the STEP randomized trial","volume":"80","author":"Yang","year":"2023","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.jacc.2026.05.005_bib30","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/ajh\/hpaf205","article-title":"GLP-1 receptor agonists and blood pressure: a state-of-the-art review of mechanisms, evidence, and clinical implications","volume":"39","author":"Moiz","year":"2025","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jacc.2026.05.005_bib31","series-title":"U.S. Food and Drug Administration. Novel Drug Approvals for","year":"2024"},{"issue":"2","key":"10.1016\/j.jacc.2026.05.005_bib32","doi-asserted-by":"crossref","DOI":"10.1161\/HYPERTENSIONAHA.125.25563","article-title":"Aprocitentan in patients with chronic kidney disease and resistant hypertension","volume":"83","author":"Rossignol","year":"2025","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.jacc.2026.05.005_bib33","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/ndt\/gfae263","article-title":"The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial","volume":"40","author":"Judge","year":"2025","journal-title":"Nephrol Dial Transplant"},{"issue":"27","key":"10.1016\/j.jacc.2026.05.005_bib34","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa2110730","article-title":"Chlorthalidone for hypertension in advanced chronic kidney disease","volume":"385","author":"Agarwal","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jacc.2026.05.005_bib35","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.jacc.2025.06.012","article-title":"Aldosterone and aldosterone modulation in cardio-kidney diseases","volume":"86","author":"Fioretti","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.jacc.2026.05.005_bib36","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1001\/jama.2023.16029","article-title":"Aldosterone synthase inhibition with lorundrostat for uncontrolled hypertension: the Target-HTN randomized clinical trial","volume":"330","author":"Laffin","year":"2023","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.jacc.2026.05.005_bib37","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1001\/jama.2025.9413","article-title":"Lorundrostat in participants with uncontrolled hypertension and treatment-resistant hypertension: the Launch-HTN randomized clinical trial","volume":"334","author":"Saxena","year":"2025","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.jacc.2026.05.005_bib38","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa2213169","article-title":"Phase 2 trial of Baxdrostat for treatment-resistant hypertension","volume":"388","author":"Freeman","year":"2023","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.jacc.2026.05.005_bib39","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1056\/NEJMoa2507109","article-title":"Efficacy and safety of baxdrostat in uncontrolled and resistant hypertension","volume":"393","author":"Flack","year":"2025","journal-title":"N Engl J Med"},{"issue":"10532","key":"10.1016\/j.jacc.2026.05.005_bib40","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S0140-6736(25)02549-8","article-title":"Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"407","author":"Azizi","year":"2026","journal-title":"Lancet"},{"issue":"10424","key":"10.1016\/j.jacc.2026.05.005_bib41","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0140-6736(23)02408-X","article-title":"Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial","volume":"403","author":"Tuttle","year":"2024","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jacc.2026.05.005_bib42","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2208391","article-title":"Zilebesiran, an RNA interference therapeutic agent for hypertension","volume":"389","author":"Desai","year":"2023","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jacc.2026.05.005_bib43","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1001\/jama.2024.0728","article-title":"RNA interference with zilebesiran for mild to moderate hypertension: the KARDIA-1 randomized clinical trial","volume":"331","author":"Bakris","year":"2024","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jacc.2026.05.005_bib44","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1001\/jama.2025.6681","article-title":"Add-on treatment with zilebesiran for inadequately controlled hypertension: the KARDIA-2 randomized clinical trial","volume":"334","author":"Desai","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.05.005_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102789","article-title":"GLP-1-based therapies for the treatment of resistant hypertension in individuals with overweight or obesity: a review","volume":"75","author":"Jarade","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"4","key":"10.1016\/j.jacc.2026.05.005_bib46","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1161\/HYPERTENSIONAHA.123.22022","article-title":"Tirzepatide reduces 24-hour ambulatory blood pressure in adults with body mass index \u226527 kg\/m: SURMOUNT-1 ambulatory blood pressure monitoring substudy","volume":"81","author":"de Lemos","year":"2024","journal-title":"Hypertension"},{"issue":"24","key":"10.1016\/j.jacc.2026.05.005_bib47","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jacc.2026.05.005_bib48","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.jacc.2023.11.032","article-title":"Randomized trial of effect of bariatric surgery on blood pressure after 5 years","volume":"83","author":"Schiavon","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.jacc.2026.05.005_bib49","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1001\/jama.2023.0713","article-title":"Endovascular ultrasound renal denervation to treat hypertension: the RADIANCE II randomized clinical trial","volume":"329","author":"Azizi","year":"2023","journal-title":"JAMA"},{"issue":"10293","key":"10.1016\/j.jacc.2026.05.005_bib50","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/S0140-6736(21)00788-1","article-title":"Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial","volume":"397","author":"Azizi","year":"2021","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.jacc.2026.05.005_bib51","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1161\/CIRCULATIONAHA.123.066941","article-title":"Patient-level pooled analysis of endovascular ultrasound renal denervation or a sham procedure 6 months after medication escalation: the RADIANCE clinical trial program","volume":"149","author":"Azizi","year":"2024","journal-title":"Circulation"},{"issue":"10234","key":"10.1016\/j.jacc.2026.05.005_bib52","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/S0140-6736(20)30554-7","article-title":"Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial","volume":"395","author":"B\u00f6hm","year":"2020","journal-title":"Lancet"},{"issue":"10137","key":"10.1016\/j.jacc.2026.05.005_bib53","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1016\/S0140-6736(18)30951-6","article-title":"Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial","volume":"391","author":"Kandzari","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.05.005_bib54","article-title":"Kidney denervation: latest breakthroughs and insights","author":"Bahrainwala","year":"2025","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.jacc.2026.05.005_bib55","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1161\/HYPERTENSIONAHA.123.22251","article-title":"Impact of antihypertensive medication changes after renal denervation among different patient groups: SPYRAL HTN-ON MED","volume":"81","author":"Townsend","year":"2024","journal-title":"Hypertension"},{"issue":"17","key":"10.1016\/j.jacc.2026.05.005_bib56","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1136\/heartjnl-2022-321496","article-title":"Hypertension therapy using fixed-dose polypills that contain at least three medications","volume":"109","author":"O'Hagan","year":"2023","journal-title":"Heart"},{"issue":"10305","key":"10.1016\/j.jacc.2026.05.005_bib57","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S0140-6736(21)01922-X","article-title":"Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial","volume":"398","author":"Chow","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jacc.2026.05.005_bib58","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1001\/jama.2018.10359","article-title":"Fixed low-dose triple combination antihypertensive medication vs usual care for blood pressure control in patients with mild to moderate hypertension in Sri Lanka: a randomized clinical trial","volume":"320","author":"Webster","year":"2018","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.jacc.2026.05.005_bib59","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2023.0720","article-title":"Efficacy and safety of low-dose triple and quadruple combination pills vs monotherapy, usual care, or placebo for the initial management of hypertension: a systematic review and meta-analysis","volume":"8","author":"Wang","year":"2023","journal-title":"JAMA Cardiol"}],"container-title":["JACC"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109726064892?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109726064892?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T23:57:57Z","timestamp":1789775877000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109726064892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":59,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0735109726064892"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2026.05.005","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypertension at an Inflection Point","name":"articletitle","label":"Article Title"},{"value":"JACC","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2026.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier on behalf of the American College of Cardiology Foundation","name":"copyright","label":"Copyright"}]}}